South San Francisco, CA, United States of America

Jacob Glanville

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Journey of Jacob Glanville

Introduction

Jacob Glanville is a prominent inventor based in South San Francisco, California. He is known for his significant contributions to the field of biomedical research and innovation. With a unique perspective on treating hematopoietic diseases and cancers, Jacob has developed pioneering methods and compositions that aim to improve patient outcomes.

Latest Patents

Jacob Glanville is credited with one notable patent: "Compositions and methods for the depletion of CD117+ cells." This invention provides vital compositions and methods for the depletion of CD117+ cells, which is crucial for treating various hematopoietic diseases, metabolic disorders, cancers like acute myeloid leukemia (AML), and autoimmune diseases. The patent describes antibodies, antigen-binding fragments, and conjugates that can effectively deplete populations of CD117+ cells in patients, thus enhancing treatment pathways and improving the success of hematopoietic stem cell transplants.

Career Highlights

Jacob's dedication to research and innovation has established him as a leading figure in the field. He works at Crispr Therapeutics AG, where he focuses on developing cutting-edge solutions that are reshaping the landscape of gene editing and biotechnology. His work directly contributes to advancements in therapies that target critical health challenges faced by many patients.

Collaborations

At Crispr Therapeutics AG, Jacob collaborates with esteemed colleagues, including Bradley R. Pearse and Michael Cooke. Together, they explore innovative avenues in therapeutic development, pooling their expertise to foster advancements in biotechnology and medical treatments.

Conclusion

Jacob Glanville’s contributions to the field of biomedical research exemplify the spirit of innovation. His work on the depletion of CD117+ cells represents a significant advancement in treating hematopoietic diseases and various cancers. As he continues his journey at Crispr Therapeutics AG, the medical community and patients alike stand to benefit from his groundbreaking inventions and collaborative efforts.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…